Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation reports news on its Omnipod product platform for diabetes care, including the Omnipod Insulin Management System and Omnipod 5 Automated Insulin Delivery System. The company’s tubeless disposable Pods provide up to three days of insulin delivery, while Omnipod 5 integrates with continuous glucose monitors and can be controlled through a compatible smartphone in the U.S. or through the Omnipod 5 Controller.
Recurring Insulet developments include quarterly results, Omnipod revenue trends, sensor-connectivity updates, clinical evidence for automated insulin delivery, and research involving fully closed-loop systems for type 2 diabetes. Company updates also cover medical device corrections, product quality actions, executive appointments, conference presentations, and the use of Omnipod technology for non-insulin subcutaneous drug delivery.
Insulet Corporation (NASDAQ: PODD) will release its third-quarter financial results on November 4, 2020, after market close. The announcement will be followed by a conference call at 4:30 p.m. ET. Insulet is recognized for its Omnipod Insulin Management System, a tubeless insulin delivery solution designed for diabetes management. The company continues to innovate with its product platform, enhancing the ease of insulin delivery for users. Interested investors can access the live call through the Investor Relations section of Insulet's website.